高级检索
当前位置: 首页 > 详情页

Development and validation of a prognostic scale for hospitalized patients with terminally ill cancer in China

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

单位: [1]Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Ctr Canc, Wuhan 430074, Peoples R China [2]Hubei Xinhua Hosp, Ctr Canc, Wuhan, Peoples R China
出处:
ISSN:

关键词: Terminal cancer Survival Prognosis End-of-life care

摘要:
The purpose of this study is to develop and validate a scale prognostic of survival in hospitalized, terminally ill cancer patients in China. Terminally ill cancer patients hospitalized at two general hospitals in China were prospectively analyzed. Patients were divided into a training cohort (n = 181) and a testing cohort (n = 128). Factors prognostic of survival were identified in the training cohort and combined into a scale, which was validated in the testing cohort. In the training cohort, eight factors associated with reduced survival were identified: low performance status, dyspnea at rest, reduced oral intake, cognitive impairment, edema, leukocytosis, and elevated urea and alanine transaminase concentrations. A prognostic prediction score was calculated for each patient, based on the weight of these eight predictors in the regression model, with scores ranging from 0 (no altered variables) to 12 (maximal altered variables). Patients with different prognostic scores had significantly different prognoses (p < 0.001). A cutoff point of a parts per thousand yen4 was optimal in categorizing patients with "low" (score < 4) and "high" (score a parts per thousand yen4) risk of survival for less than 30 days, with median survival time in these groups of 47 and 9 days, respectively. Using this cutoff point on the testing cohort, median survival time for the low and high risk groups were 66 and 11 days, respectively. We identified eight indicators predictive of poor survival in Chinese patients hospitalized with terminal cancer. A prognostic scale that includes these indicators may help in making decisions about end-of-life care.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2013]版:
大类 | 3 区 医学
小类 | 2 区 卫生保健与服务 2 区 康复医学 4 区 肿瘤学
最新[2025]版:
大类 | 3 区 医学
小类 | 2 区 康复医学 3 区 卫生保健与服务 3 区 肿瘤学
JCR分区:
出版当年[2012]版:
Q1 HEALTH CARE SCIENCES & SERVICES Q1 REHABILITATION Q2 ONCOLOGY
最新[2023]版:
Q1 REHABILITATION Q2 HEALTH CARE SCIENCES & SERVICES Q2 ONCOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2012版] 出版当年五年平均 出版前一年[2011版] 出版后一年[2013版]

第一作者:
第一作者单位: [1]Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Ctr Canc, Wuhan 430074, Peoples R China
通讯作者:
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:428 今日访问量:0 总访问量:412 更新日期:2025-04-01 建议使用谷歌、火狐浏览器 常见问题

版权所有:重庆聚合科技有限公司 渝ICP备12007440号-3 地址:重庆市两江新区泰山大道西段8号坤恩国际商务中心16层(401121)